Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones

January 5, 2024

https://www.globenewswire.com/news-release/2024/01/05/2804638/0/en/Jasper-Therapeutics-Highlights-Recent-Accomplishments-and-Key-Upcoming-Milestones.html

– EU Clinical Trials authorized for Phase 1b/2a SPOTLIGHT and BEACON studies of briquilimab in CIndU and CSU, respectively

– Patient enrollment in Phase 1b/2a SPOTLIGHT study of briquilimab in CIndU expected to commence in first quarter of 2024, initial data readout in second half of 2024

Read more at globenewswire.com

Related news for (JSPR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.